NasdaqGS:BIIBBiotechs
Should Biogen’s (BIIB) Full Global Control of Felzartamab Require Action From Investors?
Earlier this week, TJ Biopharma announced a definitive agreement under which Biogen will acquire its exclusive Greater China rights to felzartamab for up to US$850 million, giving Biogen worldwide control of the Phase 3 anti-CD38 antibody and responsibility for future development, manufacturing, and commercialization in the region.
This deal consolidates felzartamab under one owner across multiple immune-mediated diseases and multiple myeloma in China, tightening the link between Biogen’s...